---
schema_version: "secwatch.filing_event.v1"
accession: "0000318154-24-000042"
form_type: "8-K"
ticker: "AMGN"
cik: "0000318154"
company_name: "AMGEN INC"
filed_at: "2024-10-30T23:59:59+00:00"
generated_at: "2026-05-30T08:39:44.874918+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Amgen Q3 2024 revenue $8.5B (+23%), GAAP EPS $5.22 (+62%), non-GAAP EPS $5.58 (+13%)

## Summary
- Total revenues $8.5B (+23% YoY); product sales grew 24% on 29% volume growth.
- GAAP EPS $5.22 (+62%); non-GAAP EPS $5.58 (+13%).
- Free cash flow $3.3B vs $2.5B in Q3 2023.
- Rare disease portfolio contributed $1.2B in sales; 10 products had double-digit growth.
- Non-GAAP operating income $4.0B; operating margin 49.6% (down 2.4 ppt).

## SEC filing metadata
- accession: 0000318154-24-000042
- form_type: 8-K
- ticker: AMGN
- cik: 0000318154
- company_name: AMGEN INC
- filed_at: 2024-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318154/000031815424000042/0000318154-24-000042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318154/000031815424000042/amgn-20241030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000318154-24-000042
- JSON: https://secwatch.observer/filing/0000318154-24-000042.json
- Plain text: https://secwatch.observer/filing/0000318154-24-000042.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.